The current standard of care for autoimmune diseases is generally effective at managing symptoms and sustaining a good quality of life, but cures are lacking. Enter CAR T cell therapies. While all seven existing CAR Ts have been approved for hematological malignancies, the field now has its sights set on the autoimmune area.
The CAR T cell therapy market stands to gain substantially. Autoimmune diseases are characterized by a higher prevalence of active patients than cancer, and the global market is estimated to be twice that of oncology.
Vishal Singal, Partner at Beghou identified major barriers to maximizing the market. For CAR T makers to reach that broad autoimmune market, several key factors are needed to drive success, from advances in the provider ecosystem and clinical infrastructure to new considerations for patients and payers.